Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
We now rank 3rd in pharmaceutical production by volume and 14th by value
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
